About Promis Diagnostics
Promis Diagnostics is a company based in Pasadena (United States) founded in 2019. Promis Diagnostics has raised $10.8 million across 1 funding round from investors including KB Investment and Solidus Investment. The company has 9 employees as of December 31, 2021. Promis Diagnostics offers products and services including EarlyTect BCD and COVID-19 and Flu Testing. Promis Diagnostics operates in a competitive market with competitors including Viome, Invitae, Color, Everlywell and IGM Biosciences, among others.
- Headquarter Pasadena, United States
- Employees 9 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Promis Diagnostics, Inc.,
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.8 M (USD)
in 1 rounds
-
Latest Funding Round
$10.8 M (USD), Series A
Jan 20, 2020
-
Investors
KB Investment
& 1 more
-
Employee Count
9
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Promis Diagnostics
Promis Diagnostics offers a comprehensive portfolio of products and services, including EarlyTect BCD and COVID-19 and Flu Testing.
Noninvasive urine test for early bladder cancer detection with high accuracy.
Tests for detecting viral infections using biomarker-based methods.
Funding Insights of Promis Diagnostics
Promis Diagnostics has successfully raised a total of $10.8M through 1 strategic funding round. The most recent funding activity was a Series A round of $10.8 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Promis Diagnostics
Promis Diagnostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include KB Investment and Solidus Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund investing in early-stage tech startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Promis Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Promis Diagnostics
Investment portfolio details for Promis Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Promis Diagnostics
Detailed financials for Promis Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Promis Diagnostics Comparisons
Peer comparison for Promis Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Promis Diagnostics
Promis Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viome, Invitae, Color, Everlywell and IGM Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Machine learning-based bioinformatics solutions for health insights are provided.
|
|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
At-home health tests for biomarkers, nutrition, and hormone analysis.
|
|
| Locked | Locked | Locked |
Antibodies for cancer and infectious disease treatments are developed.
|
|
| Locked | Locked | Locked |
Personalized therapeutics are developed using genomic data for rare diseases.
|
Detailed competitors of Promis Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Promis Diagnostics
Complete news archive for Promis Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Promis Diagnostics
Promis Diagnostics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Promis Diagnostics is headquartered in Pasadena, United States. It is registered at Pasadena, California, United States.
Promis Diagnostics is a funded company, having raised a total of $10.8M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Promis Diagnostics is 9.
Promis Diagnostics was founded in 2019 in Pasadena, United States, focusing on biotechnology for cancer detection. Non-invasive diagnostic platforms are being developed to identify biomarkers such as DNA methylation and DNA repair genes. Stool-based tests are utilized for colorectal cancer screening. Operations center on advancing these technologies to support early detection in the medical diagnostics sector.
Promis Diagnostics's top competitors include Viome, IGM Biosciences and Variant Bio.
Promis Diagnostics offers EarlyTect BCD and COVID-19 and Flu Testing.
Promis Diagnostics has 2 investors. Key investors include KB Investment, and Solidus Investment.